| P2093 | author name string | Yasuharu Nishimura | |
| | Satoru Senju | |
| | Shinya Hirata | |
| | Satoshi Fukushima | |
| | Daiki Fukuma | |
| | Yutaka Motomura | |
| | Hidetake Matsuyoshi | |
| | Yusuke Matsunaga | |
| P2860 | cites work | Differentiation of human embryonic stem cells into immunostimulatory dendritic cells under feeder-free culture conditions. | Q51948437 |
| | Generation of immunogenic dendritic cells from human embryonic stem cells without serum and feeder cells. | Q53503551 |
| | Migration of human dendritic cells after injection in patients with metastatic malignancies | Q77804763 |
| | Generation and genetic modification of dendritic cells derived from mouse embryonic stem cells | Q78447709 |
| | Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Q24675931 |
| | Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors | Q27860937 |
| | Induction of pluripotent stem cells from adult human fibroblasts by defined factors | Q27860967 |
| | Generation of germline-competent induced pluripotent stem cells | Q28131699 |
| | An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow | Q29615498 |
| | Taking dendritic cells into medicine | Q29619243 |
| | The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells | Q32010148 |
| | Dendritic cells as therapeutic vaccines against cancer | Q36085614 |
| | Designer blood: creating hematopoietic lineages from embryonic stem cells. | Q36299248 |
| | The PD-1-PD-L pathway in immunological tolerance | Q36405777 |
| | Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+ progenitors | Q37328520 |
| | Found in translation: the human equivalent of mouse CD8+ dendritic cells | Q37761804 |
| | Pluripotent stem cell-derived dendritic cells for immunotherapy | Q37762024 |
| | Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells | Q39856765 |
| | Activation of antigen-specific cytotoxic T lymphocytes by beta 2-microglobulin or TAP1 gene disruption and the introduction of recipient-matched MHC class I gene in allogeneic embryonic stem cell-derived dendritic cells | Q39926680 |
| | Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells | Q39999811 |
| | Genetically manipulated human embryonic stem cell-derived dendritic cells with immune regulatory function | Q40095781 |
| | Efficient establishment of human embryonic stem cell lines and long-term maintenance with stable karyotype by enzymatic bulk passage | Q40278874 |
| | Directed differentiation of human embryonic stem cells into functional dendritic cells through the myeloid pathway | Q40313182 |
| | Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. | Q40314216 |
| | Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells | Q40338086 |
| | Cancer prevention with semi-allogeneic ES cell-derived dendritic cells | Q40396294 |
| | Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand. | Q40460778 |
| | Functional antigen-presenting leucocytes derived from human embryonic stem cells in vitro | Q40537295 |
| | Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination | Q40602136 |
| | Directed differentiation of dendritic cells from mouse embryonic stem cells. | Q40837850 |
| | Characterization of self-glutamic acid decarboxylase 65-reactive CD4+ T-cell clones established from Japanese patients with insulin-dependent diabetes mellitus | Q41005356 |
| | Involvement of the c-kit receptor in the adhesion of hematopoietic stem cells to stromal cells | Q41447026 |
| | Generation of lymphohematopoietic cells from embryonic stem cells in culture | Q41447884 |
| | Dual Effects of TRAIL in Suppression of Autoimmunity: The Inhibition of Th1 Cells and the Promotion of Regulatory T Cells | Q44203775 |
| | Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells | Q44986020 |
| | Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans | Q45221904 |
| | HLA-haplotype banking and iPS cells | Q47586309 |
| | Involvement of regulatory T cells in the experimental autoimmune encephalomyelitis-preventive effect of dendritic cells expressing myelin oligodendrocyte glycoprotein plus TRAIL. | Q51088950 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dendritic cell | Q506253 |
| | immunotherapy | Q1427096 |
| | pluripotency | Q1894941 |
| P304 | page(s) | 603-612 | |
| P577 | publication date | 2011-04-05 | |
| P1433 | published in | Seminars in Immunopathology | Q15724576 |
| P1476 | title | Immunotherapy with pluripotent stem cell-derived dendritic cells | |
| P478 | volume | 33 | |